Back to Search
LANCE PAGLIARO, M.D.
M.D.
Medical Oncology Physician
NPI: 1568553311IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
J2721(TX)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
59518(MN)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
ALBANY MEDICAL COLLEGE OF UNION UNIVERSITY
Class of 1987
Research & Publications (20)
Why are Cochrane hepato-biliary reviews undervalued by physicians as an aid for clinical decision-making?
PMID 19665955·Dig Liver Dis·2010
1-meta
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.
PMID 19636008·J Clin Oncol·2009
3-trial
Ischemic optic neuropathy associated with low-dose interferon alfa: report of two cases.
PMID 19194130·Am J Clin Oncol·2009
5-case
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
PMID 19349545·J Clin Oncol·2009
8-other
Multimodality therapy in penile cancer: when and which treatments?
PMID 18682961·World J Urol·2009
6-review
Choroidal and conjunctival metastases from renal cell carcinoma.
PMID 19657240·Am J Clin Oncol·2009
5-case
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
PMID 19029421·J Clin Oncol·2008
3-trial
Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring.
PMID 18395501·Dig Liver Dis·2008
1-meta
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
PMID 18635226·J Urol·2008
3-trial
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.
PMID 18362942·Br J Cancer·2008
8-other
Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma.
PMID 18454053·Anticancer Drugs·2008
5-case
High content translocation assays for pathway profiling.
PMID 16988419·Methods Mol Biol·2007
7-preclinical
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
PMID 17908974·Clin Cancer Res·2007
2-rct
Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma.
PMID 17382727·J Urol·2007
8-other
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
PMID 17971530·J Natl Cancer Inst·2007
2-rct
Fatal necrotising fasciitis associated with intramuscular injection of nonsteroidal anti-inflammatory drugs after uncomplicated endoscopic polypectomy.
PMID 17052758·J Infect·2007
5-case
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
PMID 17029276·Cancer·2006
3-trial
Protein translocation assays: key tools for accessing new biological information with high-throughput microscopy.
PMID 17110209·Methods Enzymol·2006
7-preclinical
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
PMID 17026803·Clin Genitourin Cancer·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1568553311
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile